{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:39:58Z","timestamp":1787614798393,"version":"build-2736575974"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["FAST-PS contract (HHSN271201200007I)"],"award-info":[{"award-number":["FAST-PS contract (HHSN271201200007I)"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["FAST-PS contract (HHSN271201200007I)"],"award-info":[{"award-number":["FAST-PS contract (HHSN271201200007I)"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["FAST-PS contract (HHSN271201200007I)"],"award-info":[{"award-number":["FAST-PS contract (HHSN271201200007I)"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["FAST-PS contract (HHSN271201200007I)"],"award-info":[{"award-number":["FAST-PS contract (HHSN271201200007I)"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["FAST-PS contract (HHSN271201200007I)"],"award-info":[{"award-number":["FAST-PS contract (HHSN271201200007I)"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["FAST-PS contract (HHSN271201200007I)"],"award-info":[{"award-number":["FAST-PS contract (HHSN271201200007I)"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["FAST-PS contract (HHSN271201200007I)"],"award-info":[{"award-number":["FAST-PS contract (HHSN271201200007I)"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["FAST-PS contract (HHSN271201200007I)"],"award-info":[{"award-number":["FAST-PS contract (HHSN271201200007I)"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["FAST-PS contract (HHSN271201200007I)"],"award-info":[{"award-number":["FAST-PS contract (HHSN271201200007I)"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["FAST-PS contract (HHSN271201200007I)"],"award-info":[{"award-number":["FAST-PS contract (HHSN271201200007I)"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["FAST-PS contract (HHSN271201200007I)"],"award-info":[{"award-number":["FAST-PS contract (HHSN271201200007I)"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["FAST-PS contract (HHSN271201200007I)"],"award-info":[{"award-number":["FAST-PS contract (HHSN271201200007I)"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["FAST-PS contract (HHSN271201200007I)"],"award-info":[{"award-number":["FAST-PS contract (HHSN271201200007I)"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006453","name":"Taisho Toyama Pharmaceutical Company","doi-asserted-by":"publisher","award":["Taisho Pharmaceutical R&D Inc"],"award-info":[{"award-number":["Taisho Pharmaceutical R&D Inc"]}],"id":[{"id":"10.13039\/501100006453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006453","name":"Taisho Toyama Pharmaceutical Company","doi-asserted-by":"publisher","award":["Taisho Pharmaceutical R&D Inc"],"award-info":[{"award-number":["Taisho Pharmaceutical R&D Inc"]}],"id":[{"id":"10.13039\/501100006453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006453","name":"Taisho Toyama Pharmaceutical Company","doi-asserted-by":"publisher","award":["Taisho Pharmaceutical R&D Inc"],"award-info":[{"award-number":["Taisho Pharmaceutical R&D Inc"]}],"id":[{"id":"10.13039\/501100006453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006453","name":"Taisho Toyama Pharmaceutical Company","doi-asserted-by":"publisher","award":["Taisho Pharmaceutical R&D Inc"],"award-info":[{"award-number":["Taisho Pharmaceutical R&D Inc"]}],"id":[{"id":"10.13039\/501100006453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006453","name":"Taisho Toyama Pharmaceutical Company","doi-asserted-by":"publisher","award":["Taisho Pharmaceutical R&D Inc"],"award-info":[{"award-number":["Taisho Pharmaceutical R&D Inc"]}],"id":[{"id":"10.13039\/501100006453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006453","name":"Taisho Toyama Pharmaceutical Company","doi-asserted-by":"publisher","award":["Taisho Pharmaceutical R&D Inc"],"award-info":[{"award-number":["Taisho Pharmaceutical R&D Inc"]}],"id":[{"id":"10.13039\/501100006453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006453","name":"Taisho Toyama Pharmaceutical Company","doi-asserted-by":"publisher","award":["Taisho Pharmaceutical R&D Inc"],"award-info":[{"award-number":["Taisho Pharmaceutical R&D Inc"]}],"id":[{"id":"10.13039\/501100006453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006453","name":"Taisho Toyama Pharmaceutical Company","doi-asserted-by":"publisher","award":["Taisho Pharmaceutical R&D Inc"],"award-info":[{"award-number":["Taisho Pharmaceutical R&D Inc"]}],"id":[{"id":"10.13039\/501100006453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Glutamate neurotransmission is a prioritized target for antipsychotic drug development. Two metabotropic glutamate receptor 2\/3 (mGluR2\/3) agonists (pomaglumetad [POMA] and TS-134) were assessed in two Phase Ib proof of mechanism studies of comparable designs and using identical clinical assessments and pharmacoBOLD methodology. POMA was examined in a randomized controlled trial under double-blind conditions for 10-days at doses of 80 or 320\u2009mg\/d POMA versus placebo (1:1:1 ratio). The TS-134 trial was a randomized, single-blind, 6-day study of 20 or 60\u2009mg\/d TS-134 versus placebo (5:5:2 ratio). Primary outcomes were ketamine-induced changes in pharmacoBOLD in the dorsal anterior cingulate cortex (dACC) and symptoms reflected on the Brief Psychiatric Rating Scale (BPRS). Both trials were conducted contemporaneously. 95 healthy volunteers were randomized to POMA and 63 to TS-134. High-dose POMA significantly reduced ketamine-induced BPRS total symptoms within and between-groups (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.01,\n                    <jats:italic>d<\/jats:italic>\n                    \u2009=\u2009\u22120.41;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.04,\n                    <jats:italic>d<\/jats:italic>\n                    \u2009=\u2009\u22120.44, respectively), but neither POMA dose significantly suppressed ketamine-induced dACC pharmacoBOLD. In contrast, low-dose TS-134 led to moderate to large within and between group reductions in both BPRS positive symptoms (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02,\n                    <jats:italic>d<\/jats:italic>\n                    \u2009=\u2009\u22120.36;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.008,\n                    <jats:italic>d<\/jats:italic>\n                    \u2009=\u2009\u22120.82, respectively) and dACC pharmacoBOLD (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004,\n                    <jats:italic>d<\/jats:italic>\n                    \u2009=\u2009\u22120.56;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.079,\n                    <jats:italic>d<\/jats:italic>\n                    \u2009=\u2009\u22120.50, respectively) using pooled across-study placebo data. High-dose POMA exerted significant effects on clinical symptoms, but not on target engagement, suggesting a higher dose may yet be needed, while the low dose of TS-134 showed evidence of symptom reduction and target engagement. These results support further investigation of mGluR2\/3 and other glutamate-targeted treatments for schizophrenia.\n                  <\/jats:p>","DOI":"10.1038\/s41386-020-0706-z","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T10:17:29Z","timestamp":1589365049000},"page":"1842-1850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers"],"prefix":"10.1038","volume":"45","author":[{"given":"Joshua T.","family":"Kantrowitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Grinband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald C.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne C.","family":"Lahti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0288-309X","authenticated-orcid":false,"given":"Stephen R.","family":"Marder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Kegeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragy R.","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Sobeih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie M.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tse-Hwei","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne S.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9567-8700","authenticated-orcid":false,"given":"Junghee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Horga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Krystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Z.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Javitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"706_CR1","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","volume":"50","author":"S Kapur","year":"2001","unstructured":"Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry. 2001;50:873\u201383.","journal-title":"Biol Psychiatry."},{"key":"706_CR2","doi-asserted-by":"crossref","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939\u201351.","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"706_CR3","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085\u201397.","journal-title":"Lancet."},{"key":"706_CR4","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209\u201323.","journal-title":"N Engl J Med"},{"key":"706_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40263-017-0428-x","volume":"31","author":"JT Kantrowitz","year":"2017","unstructured":"Kantrowitz JT. Managing negative symptoms of schizophrenia: how far have we come? CNS Drugs. 2017;31:373\u201388.","journal-title":"CNS Drugs."},{"key":"706_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jpsychires.2018.07.006","volume":"108","author":"RR Girgis","year":"2019","unstructured":"Girgis RR, Zoghbi AW, Javitt DC, Lieberman JA. The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review. J Psychiatr Res. 2019;108:57\u201383.","journal-title":"J Psychiatr Res"},{"key":"706_CR7","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"DC Javitt","year":"1991","unstructured":"Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301\u20138.","journal-title":"Am J Psychiatry"},{"key":"706_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199\u2013214.","journal-title":"Arch Gen Psychiatry."},{"key":"706_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.neuropharm.2012.06.002","volume":"66","author":"BJ Kinon","year":"2013","unstructured":"Kinon BJ, Gomez JC. Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia. Neuropharmacology. 2013;66:82\u20136.","journal-title":"Neuropharmacology"},{"key":"706_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/JCP.0000000000000722","volume":"37","author":"JT Kantrowitz","year":"2017","unstructured":"Kantrowitz JT, Nolan KA, Epstein ML, Lehrfeld N, Shope C, Petkova E, et al. Neurophysiological effects of bitopertin in schizophrenia. J Clin Psychopharmacol. 2017;37:447\u201351.","journal-title":"J Clin Psychopharmacol"},{"key":"706_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/JCP.0000000000000073","volume":"34","author":"JH Schoemaker","year":"2014","unstructured":"Schoemaker JH, Jansen WT, Schipper J, Szegedi A. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. J Clin Psychopharmacol. 2014;34:190\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"706_CR12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s11682-018-9967-0","volume":"13","author":"I Suridjan","year":"2019","unstructured":"Suridjan I, Comley RA, Rabiner EA. The application of positron emission tomography (PET) imaging in CNS drug development. Brain Imaging Behav. 2019;13:354\u201365.","journal-title":"Brain Imaging Behav"},{"key":"706_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1001\/jamapsychiatry.2017.3572","volume":"75","author":"DC Javitt","year":"2018","unstructured":"Javitt DC, Carter CS, Krystal JH, Kantrowitz JT, Girgis RR, Kegeles LS, et al. Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders: a randomized clinical trial. JAMA Psychiatry. 2018;75:11\u20139.","journal-title":"JAMA Psychiatry"},{"key":"706_CR14","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","volume":"17","author":"B Moghaddam","year":"1997","unstructured":"Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921\u20137.","journal-title":"J Neurosci."},{"key":"706_CR15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.biopsych.2011.11.006","volume":"71","author":"GM Chowdhury","year":"2012","unstructured":"Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G. (1)H-[(1)(3)C]-nuclear magnetic resonance spectroscopy measures of ketamine\u2019s effect on amino acid neurotransmitter metabolism. Biol Psychiatry. 2012;71:1022\u20135.","journal-title":"Biol Psychiatry."},{"key":"706_CR16","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1523\/JNEUROSCI.16-06-02034.1996","volume":"16","author":"HC Grunze","year":"1996","unstructured":"Grunze HC, Rainnie DG, Hasselmo ME, Barkai E, Hearn EF, McCarley RW, et al. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci. 1996;16:2034\u201343.","journal-title":"J Neurosci."},{"key":"706_CR17","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/nbm.1772","volume":"24","author":"DL Rothman","year":"2011","unstructured":"Rothman DL, De Feyter HM, de Graaf RA, Mason GF, Behar KL. 13C MRS studies of neuroenergetics and neurotransmitter cycling in humans. NMR Biomed. 2011;24:943\u201357.","journal-title":"NMR Biomed"},{"key":"706_CR18","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/WNR.0000000000001000","volume":"29","author":"AA Vijayakumari","year":"2018","unstructured":"Vijayakumari AA, Thomas B, Menon RN, Kesavadas C. Association between glutamate\/glutamine and blood oxygen level dependent signal in the left dorsolateral prefrontal region during verbal working memory. Neuroreport. 2018;29:478\u201382.","journal-title":"Neuroreport"},{"key":"706_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.neuroimage.2017.04.030","volume":"155","author":"B Ip","year":"2017","unstructured":"Ip B, Berrington A, Hess AT, Parker AJ, Emir UE, Bridge H. Combined fMRI-MRS acquires simultaneous glutamate and BOLD-fMRI signals in the human brain. Neuroimage. 2017;155:113\u20139.","journal-title":"Neuroimage"},{"key":"706_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.neuroscience.2012.09.039","volume":"227","author":"B Enzi","year":"2012","unstructured":"Enzi B, Duncan NW, Kaufmann J, Tempelmann C, Wiebking C, Northoff G. Glutamate modulates resting state activity in the perigenual anterior cingulate cortex - a combined fMRI-MRS study. Neuroscience. 2012;227:102\u20139.","journal-title":"Neuroscience"},{"key":"706_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.neuroscience.2017.09.037","volume":"365","author":"M Cleve","year":"2017","unstructured":"Cleve M, Gussew A, Wagner G, Bar KJ, Reichenbach JR. Assessment of intra- and inter-regional interrelations between GABA+, Glx and BOLD during pain perception in the human brain - a combined (1)H fMRS and fMRI study. Neuroscience. 2017;365:125\u201336.","journal-title":"Neuroscience"},{"key":"706_CR22","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1038\/sj.npp.1301547","volume":"33","author":"A Gozzi","year":"2008","unstructured":"Gozzi A, Large CH, Schwarz A, Bertani S, Crestan V, Bifone A. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology. 2008;33:1690\u2013703.","journal-title":"Neuropsychopharmacology."},{"key":"706_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.neuron.2013.02.011","volume":"78","author":"SA Schobel","year":"2013","unstructured":"Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I, et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron. 2013;78:81\u201393.","journal-title":"Neuron."},{"key":"706_CR24","doi-asserted-by":"crossref","unstructured":"Lieberman JA, Girgis RR, Brucato G, Moore H, Provenzano F, Kegeles L, et al. Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention. Mol Psychiatry. 2018;23:1764\u201372.","DOI":"10.1038\/mp.2017.249"},{"key":"706_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.neuroimage.2012.09.037","volume":"64","author":"S De Simoni","year":"2013","unstructured":"De Simoni S, Schwarz AJ, O\u2019Daly OG, Marquand AF, Brittain C, Gonzales C, et al. Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. Neuroimage. 2013;64:75\u201390.","journal-title":"Neuroimage."},{"key":"706_CR26","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","volume":"281","author":"B Moghaddam","year":"1998","unstructured":"Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998;281:1349\u201352.","journal-title":"Science."},{"key":"706_CR27","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0306-4522(02)00652-8","volume":"117","author":"DS Lorrain","year":"2003","unstructured":"Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience. 2003;117:697\u2013706.","journal-title":"Neuroscience"},{"key":"706_CR28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1124\/jpet.110.173880","volume":"336","author":"CL Chin","year":"2011","unstructured":"Chin CL, Upadhyay J, Marek GJ, Baker SJ, Zhang M, Mezler M, et al. Awake rat pharmacological magnetic resonance imaging as a translational pharmacodynamic biomarker: metabotropic glutamate 2\/3 agonist modulation of ketamine-induced blood oxygenation level dependence signals. J Pharm Exp Ther. 2011;336:709\u201315.","journal-title":"J Pharm Exp Ther"},{"key":"706_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00213-007-0758-3","volume":"193","author":"LM Rorick-Kehn","year":"2007","unstructured":"Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, et al. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2\/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology. 2007;193:121\u201336.","journal-title":"Psychopharmacology"},{"key":"706_CR30","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S0024-3205(03)00509-5","volume":"73","author":"K Takamori","year":"2003","unstructured":"Takamori K, Hirota S, Chaki S, Tanaka M. Antipsychotic action of selective group II metabotropic glutamate receptor agonist MGS0008 and MGS0028 on conditioned avoidance responses in the rat. Life Sci. 2003;73:1721\u20138.","journal-title":"Life Sci."},{"key":"706_CR31","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00213-018-4877-9","volume":"235","author":"MA Mehta","year":"2018","unstructured":"Mehta MA, Schmechtig A, Kotoula V, McColm J, Jackson K, Brittain C, et al. Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects. Psychopharmacology. 2018;235:1875\u201386.","journal-title":"Psychopharmacology"},{"key":"706_CR32","first-page":"758212","volume":"2014","author":"DH Adams","year":"2014","unstructured":"Adams DH, Zhang L, Millen BA, Kinon BJ, Gomez JC. Pomaglumetad methionil (LY2140023 monohydrate) and aripiprazole in patients with schizophrenia: a phase 3, multicenter, double-blind comparison. Schizophrenia Res Treat. 2014;2014:758212.","journal-title":"Schizophrenia Res Treat"},{"key":"706_CR33","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","volume":"78","author":"BJ Kinon","year":"2015","unstructured":"Kinon BJ, Millen BA, Zhang L, McKinzie DL. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry. 2015;78:754\u201362.","journal-title":"Biol Psychiatry."},{"key":"706_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/JCP.0b013e318218dcd5","volume":"31","author":"BJ Kinon","year":"2011","unstructured":"Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011;31:349\u201355.","journal-title":"J Clin Psychopharmacol"},{"key":"706_CR35","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Arlington, VA: American Psychiatric Association. 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"706_CR36","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DE. The brief psychiatric rating scale. Psychol Rep. 1962;10:799\u2013812.","journal-title":"Psychol Rep"},{"key":"706_CR37","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/0269881118822263","volume":"33","author":"R McMillan","year":"2019","unstructured":"McMillan R, Forsyth A, Campbell D, Malpas G, Maxwell E, Dukart J, et al. Temporal dynamics of the pharmacological MRI response to subanaesthetic ketamine in healthy volunteers: A simultaneous EEG\/fMRI study. J Psychopharmacol. 2019;33:219\u201329.","journal-title":"J Psychopharmacol."},{"key":"706_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fpsyt.2019.00049","volume":"10","author":"F Nicoletti","year":"2019","unstructured":"Nicoletti F, Orlando R, Di Menna L, Cannella M, Notartomaso S, Mascio G, et al. Targeting mGlu receptors for optimization of antipsychotic activity and disease-modifying effect in schizophrenia. Front Psychiatry. 2019;10:49.","journal-title":"Front Psychiatry."},{"key":"706_CR39","doi-asserted-by":"publisher","first-page":"9594","DOI":"10.1523\/JNEUROSCI.18-23-09594.1998","volume":"18","author":"V Bruno","year":"1998","unstructured":"Bruno V, Battaglia G, Casabona G, Copani A, Caciagli F, Nicoletti F. Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-beta. J Neurosci. 1998;18:9594\u2013600.","journal-title":"J Neurosci."},{"key":"706_CR40","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1523\/JNEUROSCI.4456-04.2005","volume":"25","author":"DL Taylor","year":"2005","unstructured":"Taylor DL, Jones F, Kubota ES, Pocock JM. Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand. J Neurosci. 2005;25:2952\u201364.","journal-title":"J Neurosci."},{"key":"706_CR41","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1124\/mol.110.067488","volume":"79","author":"F Caraci","year":"2011","unstructured":"Caraci F, Molinaro G, Battaglia G, Giuffrida ML, Riozzi B, Traficante A, et al. II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer\u2019s disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. Mol Pharmacol. 2011;79:618\u201326.","journal-title":"Mol Pharmacol."},{"key":"706_CR42","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1124\/mol.108.052316","volume":"75","author":"L Iacovelli","year":"2009","unstructured":"Iacovelli L, Molinaro G, Battaglia G, Motolese M, Di Menna L, Alfiero M, et al. Regulation of group II metabotropic glutamate receptors by G protein-coupled receptor kinases: mGlu2 receptors are resistant to homologous desensitization. Mol Pharmacol. 2009;75:991\u20131003.","journal-title":"Mol Pharmacol."},{"key":"706_CR43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1124\/jpet.108.136861","volume":"326","author":"MJ Fell","year":"2008","unstructured":"Fell MJ, Svensson KA, Johnson BG, Schoepp DD. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2\/3 receptor agonist (-)-(1\u2009R,4\u2009S,5\u2009S,6\u2009S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharm Exp Ther. 2008;326:209\u201317.","journal-title":"J Pharm Exp Ther"},{"key":"706_CR44","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/mp.2016.129","volume":"22","author":"LE Jin","year":"2017","unstructured":"Jin LE, Wang M, Yang ST, Yang Y, Galvin VC, Lightbourne TC, et al. mGluR2\/3 mechanisms in primate dorsolateral prefrontal cortex: evidence for both presynaptic and postsynaptic actions. Mol Psychiatry. 2017;22:1615\u201325.","journal-title":"Mol Psychiatry."},{"key":"706_CR45","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.neuroimage.2012.09.044","volume":"65","author":"N Khalili-Mahani","year":"2013","unstructured":"Khalili-Mahani N, Chang C, van Osch MJ, Veer IM, van Buchem MA, Dahan A, et al. The impact of \u201cphysiological correction\u201d on functional connectivity analysis of pharmacological resting state fMRI. Neuroimage. 2013;65:499\u2013510.","journal-title":"Neuroimage."},{"key":"706_CR46","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.neuroimage.2008.09.029","volume":"44","author":"C Chang","year":"2009","unstructured":"Chang C, Cunningham JP, Glover GH. Influence of heart rate on the BOLD signal: the cardiac response function. Neuroimage. 2009;44:857\u201369.","journal-title":"Neuroimage."},{"key":"706_CR47","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/ijnp\/pyx055","volume":"20","author":"T Liebe","year":"2017","unstructured":"Liebe T, Li S, Lord A, Colic L, Krause AL, Batra A, et al. Factors influencing the cardiovascular response to subanesthetic ketamine: a randomized, placebo-controlled trial. Int J Neuropsychopharmacol. 2017;20:909\u201318.","journal-title":"Int J Neuropsychopharmacol"},{"key":"706_CR48","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/00000542-200301000-00021","volume":"98","author":"YH Jin","year":"2003","unstructured":"Jin YH, Bailey TW, Doyle MW, Li BY, Chang KS, Schild JH, et al. Ketamine differentially blocks sensory afferent synaptic transmission in medial nucleus tractus solitarius (mNTS). Anesthesiology. 2003;98:121\u201332.","journal-title":"Anesthesiology."},{"key":"706_CR49","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s0054080020207","volume":"2","author":"S Hoka","year":"1988","unstructured":"Hoka S, Takeshita A, Sasaki T, Yoshitake J. Preservation of baroreflex control of vascular resistance under ketamine anesthesia in rats. J Anesthesia. 1988;2:207\u201312.","journal-title":"J Anesthesia"},{"key":"706_CR50","first-page":"704","volume":"53","author":"S Slogoff","year":"1974","unstructured":"Slogoff S, Allen GW. The role of baroreceptors in the cardiovascular response to ketamine. Anesth Analg. 1974;53:704\u20137.","journal-title":"Anesth Analg."},{"key":"706_CR51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00000542-199301000-00022","volume":"78","author":"A Ogawa","year":"1993","unstructured":"Ogawa A, Uemura M, Kataoka Y, Ol K, Inokuchi T. Effects of ketamine on cardiovascular responses mediated by N-methyl-D-aspartate receptor in the rat nucleus tractus solitarius. Anesthesiology. 1993;78:163\u20137.","journal-title":"Anesthesiology."},{"key":"706_CR52","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ejphar.2013.04.046","volume":"713","author":"LH Camargo","year":"2013","unstructured":"Camargo LH, Alves FH, Biojone C, Correa FM, Resstel LB, Crestani CC. Involvement of N-methyl-D-aspartate glutamate receptor and nitric oxide in cardiovascular responses to dynamic exercise in rats. Eur J Pharm. 2013;713:16\u201324.","journal-title":"Eur J Pharm"},{"key":"706_CR53","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00424-017-2083-y","volume":"470","author":"NC Ferreira-Junior","year":"2018","unstructured":"Ferreira-Junior NC, Lagatta DC, Resstel LBM. Glutamatergic, GABAergic, and endocannabinoid neurotransmissions within the dorsal hippocampus modulate the cardiac baroreflex function in rats. Pflug Arch. 2018;470:395\u2013411.","journal-title":"Pflug Arch."},{"key":"706_CR54","doi-asserted-by":"publisher","unstructured":"Gillies MJ, Huang Y, Hyam JA, Aziz TZ, Green AL. Direct neurophysiological evidence for a role of the human anterior cingulate cortex in central command. Auton. Neurosci. https:\/\/doi.org\/10.1016\/j.autneu.2018.09.004. 2018.","DOI":"10.1016\/j.autneu.2018.09.004"},{"key":"706_CR55","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00213-008-1271-z","volume":"201","author":"A Gozzi","year":"2008","unstructured":"Gozzi A, Herdon H, Schwarz A, Bertani S, Crestan V, Turrini G, et al. Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat. Psychopharmacology. 2008;201:273\u201384.","journal-title":"Psychopharmacology"},{"key":"706_CR56","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.neuroscience.2010.02.057","volume":"168","author":"EA Hackler","year":"2010","unstructured":"Hackler EA, Byun NE, Jones CK, Williams JM, Baheza R, Sengupta S, et al. Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation. Neuroscience. 2010;168:209\u201318.","journal-title":"Neuroscience"},{"key":"706_CR57","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/npp.2013.290","volume":"39","author":"N Gass","year":"2014","unstructured":"Gass N, Schwarz AJ, Sartorius A, Schenker E, Risterucci C, Spedding M, et al. Sub-anesthetic ketamine modulates intrinsic BOLD connectivity within the hippocampal-prefrontal circuit in the rat. Neuropsychopharmacology. 2014;39:895\u2013906.","journal-title":"Neuropsychopharmacology."},{"key":"706_CR58","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00213-006-0344-0","volume":"186","author":"CL Littlewood","year":"2006","unstructured":"Littlewood CL, Jones N, O\u2019Neill MJ, Mitchell SN, Tricklebank M, Williams SC. Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacology. 2006;186:64\u201381.","journal-title":"Psychopharmacology"},{"key":"706_CR59","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00213-007-0771-6","volume":"192","author":"GS Linn","year":"2007","unstructured":"Linn GS, O\u2019Keeffe RT, Lifshitz K, Schroeder C, Javitt DC. Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine. Psychopharmacology. 2007;192:27\u201338.","journal-title":"Psychopharmacology"},{"key":"706_CR60","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1124\/jpet.111.188797","volume":"341","author":"S Baker","year":"2012","unstructured":"Baker S, Chin CL, Basso AM, Fox GB, Marek GJ, Day M. Xanomeline modulation of the blood oxygenation level-dependent signal in awake rats: development of pharmacological magnetic resonance imaging as a translatable pharmacodynamic biomarker for central activity and dose selection. J Pharm Exp Ther. 2012;341:263\u201373.","journal-title":"J Pharm Exp Ther"},{"key":"706_CR61","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/npp.2014.10","volume":"39","author":"J Li","year":"2014","unstructured":"Li J, Ishiwari K, Conway MW, Francois J, Huxter J, Lowry JP, et al. Dissociable effects of antipsychotics on ketamine-induced changes in regional oxygenation and inter-regional coherence of low frequency oxygen fluctuations in the rat. Neuropsychopharmacology. 2014;39:1635\u201344.","journal-title":"Neuropsychopharmacology."},{"key":"706_CR62","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/00000542-200309000-00016","volume":"99","author":"JW Langsjo","year":"2003","unstructured":"Langsjo JW, Kaisti KK, Aalto S, Hinkka S, Aantaa R, Oikonen V, et al. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology. 2003;99:614\u201323.","journal-title":"Anesthesiology."},{"key":"706_CR63","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/00000542-200508000-00008","volume":"103","author":"JW Langsjo","year":"2005","unstructured":"Langsjo JW, Maksimow A, Salmi E, Kaisti K, Aalto S, Oikonen V, et al. S-ketamine anesthesia increases cerebral blood flow in excess of the metabolic needs in humans. Anesthesiology. 2005;103:258\u201368.","journal-title":"Anesthesiology."},{"key":"706_CR64","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/00000542-200405000-00006","volume":"100","author":"JW Langsjo","year":"2004","unstructured":"Langsjo JW, Salmi E, Kaisti KK, Aalto S, Hinkka S, Aantaa R, et al. Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans. Anesthesiology. 2004;100:1065\u201371.","journal-title":"Anesthesiology."},{"key":"706_CR65","unstructured":"Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd edn. Lawrence Erlbaum Assoc.: Hillsdale, NJ; 1988."},{"key":"706_CR66","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1038\/s41380-018-0082-9","volume":"23","author":"A Egerton","year":"2018","unstructured":"Egerton A, Broberg BV, Van Haren N, Merritt K, Barker GJ, Lythgoe DJ, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE). Mol Psychiatry. 2018;23:2145\u201355.","journal-title":"Mol Psychiatry."},{"key":"706_CR67","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/schbul\/sbv151","volume":"42","author":"E Mouchlianitis","year":"2016","unstructured":"Mouchlianitis E, Bloomfield MA, Law V, Beck K, Selvaraj S, Rasquinha N, et al. Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophr Bull. 2016;42:744\u201352.","journal-title":"Schizophr Bull."},{"key":"706_CR68","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s00406-005-0563-0","volume":"255","author":"M Soyka","year":"2005","unstructured":"Soyka M, Koch W, Moller HJ, Ruther T, Tatsch K. Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Results from a FDG-PET study. Eur Arch Psychiatry Clin Neurosci. 2005;255:308\u201312.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"706_CR69","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.schres.2013.12.013","volume":"152","author":"EM Poels","year":"2014","unstructured":"Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, et al. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res. 2014;152:325\u201332.","journal-title":"Schizophr Res."},{"key":"706_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-14-102","volume":"14","author":"TA Lane","year":"2013","unstructured":"Lane TA, Boerner T, Bannerman DM, Kew JN, Tunbridge EM, Sharp T, et al. Decreased striatal dopamine in group II metabotropic glutamate receptor (mGlu2\/mGlu3) double knockout mice. BMC Neurosci. 2013;14:102.","journal-title":"BMC Neurosci."},{"key":"706_CR71","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1046\/j.1471-4159.2000.0751147.x","volume":"75","author":"J Cartmell","year":"2000","unstructured":"Cartmell J, Perry KW, Salhoff CR, Monn JA, Schoepp DD. The potent, selective mGlu2\/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat. J Neurochem. 2000;75:1147\u201354.","journal-title":"J Neurochem"},{"key":"706_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuropharm.2004.02.015","volume":"47","author":"RG Greenslade","year":"2004","unstructured":"Greenslade RG, Mitchell SN. Selective action of (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268), a group II metabotropic glutamate receptor agonist, on basal and phencyclidine-induced dopamine release in the nucleus accumbens shell. Neuropharmacology 2004;47:1\u20138.","journal-title":"Neuropharmacology"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-020-0706-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-020-0706-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-020-0706-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T04:08:38Z","timestamp":1650514118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-020-0706-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":72,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1038\/s41386-020-0706-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.03.09.20029827","asserted-by":"object"}]},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,13]]},"assertion":[{"value":"14 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}